jich extenzivním přívodem v krátkém časovém horizontu, nebo naopak s prodlouženým podáním a rizikem jejich kumulace. V takové situaci může i přes jejich bezpečnost dojít k projevu jejich biologických účinků.

Mezi nejčastěji zmiňované účinky patří změny farmakokinetiky léčiv, aktivace imunitního systému, ovlivnění buněčné toxicity a interakce s biologickými membránami. Některé pomocné látky mohou také způsobovat alergické reakce nebo jiné orgánové toxicity, jako hepatotoxicita, dermotoxicita či mohou negativně ovlivňovat kardiovaskulární systém. Vzhledem k těmto potenciálním rizikům je nutné věnovat zvýšenou pozornost výběru a hodnocení pomocných látek při vývoji nových intravenózních formulací, ale i použití stávajících léčivých přípravků.

Budoucí výzkum by měl být zaměřen na podrobnější zmapování těchto účinků a na identifikaci bezpečných profilů pomocných látek, aby byla zajištěna co nejvyšší účinnost a bezpečnost intravenózně podávaných léčiv. Vigilance ve smyslu biologických efektů pomocných látek je jednou z klíčových iniciativ pro zajišťování bezpečné farmakoterapie, nikoli jen farmakovigilance zaměřená na farmakologicky účinné látky, jak je tomu doposud například při hodnocení generik a biosimilars.

LITERATURA

1. Caballero ML, Krantz MS, Quirce S, et al. Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions. J Allergy Clin Immunol Pract. 2021;9(8):2968-2982.

2. Demey HE, Daelemans RA, Verpooten GA, et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med. 1988;14(3):221-226.

3. Neale BW, Mesler EL, Young M, et al. Propylene glycol-induced lactic acidosis in a patient with normal renal function: a proposed mechanism and monitoring recommendations. Ann Pharmacother. 2005;39(10):1732-1736.

4. Golden TR, Solnicky V, Wadeea R, et al. Pentobarbital-induced lactic acidosis following status epilepticus barbiturate coma. BMJ Case Rep. 2018;2018:bcr2017223482.

5. Smedley LW, Rios D, Barthol CA, et al. Iatrogenic Propylene Glycol Intoxication Due to High-Dose Pentobarbital for Refractory Intracranial Hypertension: A Case Report. J Pharm Pract. 2020;33(6):895-898.

6. Shi GH, Pisupati K, Parker JG, et al. Subcutaneous Injection Site Pain of Formulation Matrices. Pharm Res. 2021;38(5):779-793.

7. European Medicines Agency [on-line]. Annex to the European Commission guideline on „Excipients in the labelling and package leaflet of medicinal products for human use". Available from: https://www.ema.europa.eu/en/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use.

8. European Medicines Agency [on-line]. Excipients labelling. Available from: https://www.ema.europa.eu/en/product-information-requirements/excipients-labelling.

9. Státní ústav pro kontrolu léčiv [on-line]. Pomocné látky povinně uváděné na obalech a odpovídající text v příbalové informaci – aktualizovaná verze přílohy pro ČR. Available from: https://www.sukl.cz/leciva/pomocne-latky-povinne-uvadene-na-obalech-a-odpovidajici-text.

10. Cao DJ, Aldy K, Hsu S, et al. Review of Health Consequences of Electronic Cigarettes and the Outbreak of Electronic Cigarette, or Vaping, Product Use-Associated Lung Injury. J Med Toxicol. 2020;16(3):295-310.

11. Medications Containing Propylene Glycol and Risk of Anion Gap Metabolic Acidosis [on-line]. Available from: https://www.ebmconsult.com/articles/medications-containing-propylene-glycol-risk-anion-gap-metabolic-acidosis.

12. Wilson KC, Reardon C, Theodore AC, et al. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest. 2005;128(3):1674-1681.

13. Speth PA, Vree TB, Neilen NF, et al. Propylene glycol pharmacokinetics and effects after intravenous infusion in humans. Ther Drug Monit. 1987;9(3):255-258.

14. Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219.

15. Lewis AS, Boomhower SR, Marsh CM, et al. Considerations for deriving a safe intake of propylene glycol. Food Chem Toxicol. 2024;186:114460.

16. European Medicines Agency [on-line]. Questions and answers on propylene glycol used as an excipient in medicinal products for human use. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-propylene-glycol-used-excipient-medicinal-products-human-use_en.pdf.

17. World Health Organization [on-line]. Toxicological evaluation of certain food additives with a review of general principles and of specifications : seventeenth report of the Joint FAO/WHO Expert Committee on Food Additives, Geneva, 25 June - 4 July 1973. Available from: https://iris.who.int/bitstream/handle/10665/41072/WHO_TRS_539.pdf?sequence=1&isAllowed=y.

18. Nelsen JL, Haas CE, Habtemariam B, et al. A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. J Intensive Care Med. 2008;23(3):184-194.

19. Abu-Sawwa R, Busque K, Cokley J. Parenteral medication considerations for the ketogenic diet. American Journal of Health-System Pharmacy. 2023;80(19):1357-1363.

20. Kriegel C, Festag M, Kishore RSK, et al. Pediatric Safety of Polysorbates in Drug Formulations. Children (Basel). 2019;7(1):1.

21. Schwartzberg LS, Navari RM. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther. 2018;35(6):754-767.

22. ten Tije AJ, Loos WJ, Verweij J, et al. Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches. Clinical Pharmacology & Therapeutics. 2003;74(5):509-510.

23. Loos WJ, Baker SD, Verweij J, et al. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther. 2003;74(4):364-371.

24. Kicker JS, Haizlip JA, Buck ML. Hepatotoxicity After Continuous Amiodarone Infusion in a Postoperative Cardiac Infant. J Pediatr Pharmacol Ther. 2012;17(2):189-195.

25. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). Scientific Opinion on the re-evaluation of polyoxyethylene sorbitan monolaurate (E 432), polyoxyethylene sorbitan monooleate (E 433), polyoxyethylene sorbitan monopalmitate (E 434), polyoxyethylene sorbitan monostearate (E 435) and polyoxyethylene sorbitan tristearate (E 436) as food additives. EFSA Journal. 2015;13(7):4152.

26. European Medicines Agency [on-line]. Information for the package leaflet regarding polysorbates used as excipients in medicinal products for human use. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-regarding-polysorbates-used-excipients-medicinal-products-human-use_en.pdf.

27. Rhodes A, Eastwood JB, Smith SA. Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? Gut. 1993;34(4):565-566.

28. Boccia R, Geller RB, Clendeninn N, et al. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study. Future Oncol. 2019;15(3):297-303.

29. Rizzioli E, Incasa E, Gamberini S, et al. Acute toxic hepatitis after amiodarone intravenous loading. Am J Emerg Med. 2007;25(9):1082.e1-4.

30. Bravo AER, Drewe J, Schlienger RG, et al. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Critical Care Medicine. 2005;33(1):128.

31. Pouliot M, Bussiere J, Coppi A, et al. Polysorbate 80-Induced Anaphylactoid Reaction and the Effects on Cardiovascular Function: Dose Threshold and Species Comparison. Int J Toxicol. 2022;41(2):99-107.

32. Pannone L, D'Angelo G, Gulletta S, et al. Amiodarone in ventricular arrhythmias: still a valuable resource? RCM. 2021;22(4):1383-1392.

33. Lindquist DE, Rowe AS, Heidel E, et al. Evaluation of the Hemodynamic Effects of Intravenous Amiodarone Formulations During the Maintenance Phase Infusion. Ann Pharmacother. 2015;49(12):1317-1321.

34. Stone CA, Liu Y, Relling MV, et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533-1540.e8.

35. Turner RB, Martello JL, Malhotra A. Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: A systematic review. International Journal of Antimicrobial Agents. 2015;46(4):362-366.

36. Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291-3301.

37. Luke DR, Wood ND, Tomaszewski KE, et al. Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis. Nephrology Dialysis Transplantation. 2012;27(3):1207-1212.

38. Kiser TH, Fish DN, Aquilante CL, et al. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015;19(1):32.

39. Hoover RK, Alcorn H, Lawrence L, et al. Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment. J Clin Pharmacol. 2018;58(6):814-822.

40. Hafner V, Czock D, Burhenne J, et al. Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration. Antimicrob Agents Chemother. 2010;54(6):2596-2602.

41. Státní ústav pro kontrolu léčiv [on-line]. Databáze léků SÚKL. Available from: https://prehledy.sukl.cz/prehled_leciv.html#/.

42. Stella VJ, Rajewski RA. Sulfobutylether-β-cyclodextrin. Int J Pharm. 2020;583:119396.

43. European Medicines Agency [on-line]. Background review for cyclodextrins used as excipients. Available from: https://ema.europa.eu/en/documents/report/background-review-cyclodextrins-used-excipients-context-revision-guideline-excipients-label-and-package-leaflet-medicinal-products-human-use-draft-report_en.pdf.